Market closed
Pacific Biosciences/$PACB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pacific Biosciences
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Ticker
$PACB
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
575
Website
PACB Metrics
BasicAdvanced
$340M
-
-$1.13
1.86
-
Price and volume
Market cap
$340M
Beta
1.86
52-week high
$2.67
52-week low
$1.08
Average daily volume
8.3M
Financial strength
Current ratio
12.689
Quick ratio
10.653
Long term debt to equity
130.757
Total debt to equity
132.736
Interest coverage (TTM)
-21.67%
Management effectiveness
Return on assets (TTM)
-12.08%
Return on equity (TTM)
-51.30%
Valuation
Price to revenue (TTM)
2.032
Price to book
0.66
Price to tangible book (TTM)
-1.67
Price to free cash flow (TTM)
-1.474
Growth
Revenue change (TTM)
-23.19%
Earnings per share change (TTM)
-6.71%
3-year revenue growth (CAGR)
5.67%
3-year earnings per share growth (CAGR)
8.25%
What the Analysts think about PACB
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.
PACB Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PACB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PACB News
AllArticlesVideos
Davos Alzheimer's Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer's Disease Research in North Africa
GlobeNewsWire·3 days ago
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million
GlobeNewsWire·2 weeks ago
PacBio Grants Equity Incentive Award to New Employee
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pacific Biosciences stock?
Pacific Biosciences (PACB) has a market cap of $340M as of April 25, 2025.
What is the P/E ratio for Pacific Biosciences stock?
The price to earnings (P/E) ratio for Pacific Biosciences (PACB) stock is 0 as of April 25, 2025.
Does Pacific Biosciences stock pay dividends?
No, Pacific Biosciences (PACB) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Pacific Biosciences dividend payment date?
Pacific Biosciences (PACB) stock does not pay dividends to its shareholders.
What is the beta indicator for Pacific Biosciences?
Pacific Biosciences (PACB) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.